Medicare Enrolled
Dr. Muhammad Abbasi, M.D.
Hematology & Oncology · Mountain Lakes, NJ
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Abbasi from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Abbasi?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Abbasi
Dr. Muhammad Abbasi is a hematology & oncology specialist in Mountain Lakes, NJ, with 20 years of NPI registration. Based on federal Medicare data, Dr. Abbasi performed 50,231 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Abbasi received a total of $28,640 from 86 pharmaceutical and/or device companies across 1216 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Abbasi is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years of NPI registration
▲ Top 20% volume in NJ
$28,640 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗50,231
Medicare services
Top 20% in NJ for hematology & oncology
Not available
Unique patients (not deduplicated)
$28
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 17,000 | $43 | $90 |
| Iron infusion (Monoferric) | 8,800 | $17 | $50 |
| Denosumab injection (Prolia/Xgeva) | 7,620 | $18 | $40 |
| Epoetin alfa injection (Retacrit) for anemia An injection of a biosimilar form of epoetin alfa used for non-end-stage renal disease purposes. The dose administered is 1000 units. |
3,940 | $6 | $25 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
2,982 | $0 | $5 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,755 | $107 | $225 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,720 | $1 | $15 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
1,645 | $8 | $15 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
1,602 | $8 | $40 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
606 | $12 | $50 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
365 | $119 | $350 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
337 | $14 | $75 |
| Flow cytometry, additional marker An additional marker is tested during a flow cytometry procedure to analyze DNA or cells. This step adds specific data points to the initial analysis. |
290 | $23 | $100 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
259 | $1 | $10 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
230 | $26 | $125 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
199 | $103 | $175 |
| Hospital follow-up visit, low complexity Follow-up hospital visit for an established patient with straightforward or low-level medical decision making. The visit requires at least 25 minutes of time spent on the day of service. |
160 | $43 | $75 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
137 | $60 | $200 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
122 | $66 | $125 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
114 | $1 | $2 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
108 | $57 | $200 |
| New patient office visit, complex (60-74 min) | 89 | $194 | $500 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
40 | $50 | $100 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
35 | $159 | $296 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
33 | $150 | $275 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
30 | $78 | $165 |
| Flow cytometry DNA or cell analysis, first marker A laboratory test that uses a laser to analyze cells or DNA by detecting a specific marker on the cell surface or within the cell. |
13 | $71 | $200 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
19.2% high complexity
69.1% medium
11.7% routine
Industry Payment Transparency
Open Payments through 2024 ↗$28,640
Total received (2018-2024)
Avg $4,091/year across 7 years
Top 9% in NJ for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
86
Companies
1,216
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$2,822
2023
$1,961
2022
$1,775
2021
$1,656
2020
$3,225
2019
$4,928
2018
$12,273
Payments by company (2024)
Novartis Pharmaceuticals Corporation
$894
AstraZeneca Pharmaceuticals LP
$273
E.R. Squibb & Sons, L.L.C.
$206
SEAGEN INC.
$167
GlaxoSmithKline, LLC.
$142
Daiichi Sankyo Inc.
$123
Janssen Biotech, Inc.
$116
PFIZER INC.
$80
Merck Sharp & Dohme LLC
$74
Mirati Therapeutics, Inc.
$64
Bayer Healthcare Pharmaceuticals Inc.
$63
Ipsen Biopharmaceuticals, Inc
$57
ABBVIE INC.
$50
Eisai Inc.
$48
Genmab U.S., Inc.
$43
Kyowa Kirin, Inc.
$33
Genentech USA, Inc.
$32
Tempus AI, Inc
$25
Adaptive Biotechnologies Corporation
$21
TAIHO ONCOLOGY, INC.
$20
Legend Biotech USA Inc.
$19
Myriad Genetic Laboratories, Inc.
$18
Gilead Sciences, Inc.
$18
Coherus Biosciences Inc.
$18
Blueprint Medicines Corporation
$18
Regeneron Healthcare Solutions, Inc.
$18
Astellas Pharma US Inc
$18
Takeda Pharmaceuticals U.S.A., Inc.
$17
Karyopharm Therapeutics Inc.
$17
Exelixis Inc.
$17
ARRAY BIOPHARMA INC
$17
Celgene Corporation
$17
Incyte Corporation
$17
Amgen Inc.
$17
Lilly USA, LLC
$16
PharmaEssentia USA Corporation
$16
Aveo Pharmaceuticals, Inc.
$13
Top 3 companies account for 48.6% of 2024 payments
All-time payments by company (2018-2024) ›
Novartis Pharmaceuticals Corporation
$6,774
Bayer HealthCare Pharmaceuticals Inc.
$4,350
Puma Biotechnology, Inc.
$2,189
E.R. Squibb & Sons, L.L.C.
$1,629
AstraZeneca Pharmaceuticals LP
$1,330
Merck Sharp & Dohme Corporation
$1,079
Amgen Inc.
$1,032
Janssen Biotech, Inc.
$936
Seagen Inc.
$699
Genentech USA, Inc.
$569
GENZYME CORPORATION
$493
PFIZER INC.
$453
Pharmacyclics LLC, An AbbVie Company
$375
GlaxoSmithKline, LLC.
$368
Seattle Genetics, Inc.
$362
Daiichi Sankyo Inc.
$308
Incyte Corporation
$299
Astellas Pharma US Inc
$287
Gilead Sciences, Inc.
$261
Celgene Corporation
$245
AbbVie, Inc.
$226
Karyopharm Therapeutics Inc.
$224
Lilly USA, LLC
$196
Merck Sharp & Dohme LLC
$194
Myriad Genetic Laboratories, Inc.
$192
Eisai Inc.
$191
Foundation Medicine, Inc.
$185
Takeda Pharmaceuticals U.S.A., Inc.
$174
Regeneron Healthcare Solutions, Inc.
$173
SEAGEN INC.
$167
Mirati Therapeutics, Inc.
$161
Kyowa Kirin, Inc.
$136
Bayer Healthcare Pharmaceuticals Inc.
$132
Ipsen Biopharmaceuticals, Inc
$128
AVEO Pharmaceuticals, Inc.
$123
Celltrion USA Inc.
$105
AMAG Pharmaceuticals, Inc.
$94
Boehringer Ingelheim Pharmaceuticals, Inc.
$93
BeiGene USA, Inc.
$86
Janssen Pharmaceuticals, Inc
$83
EISAI INC.
$81
ABBVIE INC.
$80
SOBI, INC
$79
Verastem, Inc.
$78
CTI BioPharma Corp.
$72
Epizyme, Inc.,
$57
Genmab U.S., Inc.
$57
Allergan Inc.
$52
Partner Therapeutics, Inc.
$51
Spectrum Pharmaceuticals Inc.
$48
ARRAY BIOPHARMA INC
$46
JAZZ PHARMACEUTICALS INC.
$45
EMD Serono, Inc.
$44
AbbVie Inc.
$44
Rigel Pharmaceuticals, Inc.
$44
TESARO, Inc.
$42
Alexion Pharmaceuticals, Inc.
$41
Kite Pharma, Inc.
$39
Adaptive Biotechnologies Corporation
$38
Blueprint Medicines Corporation
$34
Exelixis Inc.
$30
Taiho Oncology, Inc.
$30
Clovis Oncology, Inc.
$29
Aveo Pharmaceuticals, Inc.
$29
Tempus AI, Inc
$25
G1 Therapeutics, Inc.
$24
TAIHO ONCOLOGY, INC.
$20
Biocon Biologics Inc
$19
Legend Biotech USA Inc.
$19
Coherus Biosciences Inc.
$18
Servier Pharmaceuticals LLC
$18
PharmaEssentia USA Corporation
$16
TOLMAR Pharmaceuticals, Inc.
$15
Jazz Pharmaceuticals Inc.
$15
Secura Bio, Inc.
$15
Dendreon Pharmaceuticals LLC
$15
Acceleron Pharma, Inc.
$15
TerSera Therapeutics LLC
$14
Sumitomo Pharma America, Inc.
$14
Horizon Therapeutics plc
$14
Myovant Sciences Inc.
$14
Pharmacyclics LLC, an AbbVie Company
$14
EUSA Pharma (US) LLC
$13
Advanced Accelerator Applications
$13
NOVARTIS PHARMACEUTICALS CORPORATION
$12
Sirtex Medical Inc
$10
Top 3 companies account for 46.5% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · ALIMTA · AYVAKIT · Abraxane · Alecensa · Aliqopa · Avastin · BESREMI · BOSULIF · BRAFTOVI · BRUKINSA · Blincyto · CABOMETYX · CALQUENCE · CERDELGA · COPIKTRA · COSELA · CYRAMZA · Cabometyx · Copiktra · DALVANCE · DARZALEX · Doptelet · ELAHERE · ELIGARD · ELIQUIS · ELITEK · ELREXFIO · EMPLICITI · ENHERTU · EPKINLY · ERLEADA · EVENITY · Enhertu · Epkinly · Erivedge · Erleada · FASLODEX · FERAHEME · FOTIVDA · FOUNDATIONONE · FOUNDATIONONE CDX · Fabhalta · GAZYVA · GILOTRIF · Halaven · Herceptin · IBRANCE · IMBRUVICA · IMFINZI · INLYTA · Imbruvica · Inrebic · Itovebi · JADENU · JAKAFI · JEMPERLI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kadcyla · Kyprolis · LENVIMA · LIBTAYO · LIBTAYO CEMIPLIMAB-RWLC INJECTION · LONSURF · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Leukine · Lonsurf · MEKINIST · MONJUVI · MVASI · MYLOTARG · MYRISK · NERLYNX · NINLARO · Nerlynx · Neulasta · Nexavar · Nplate · Nubeqa · OJJAARA · OPDIVO · OPDUALAG · ORGOVYX · Ogivri · Onivyde · PADCEV · PIQRAY · PLUVICTO · POTELIGEO · PRECISETUMOR · PROMACTA · PROVENGE · Padcev · Perjeta · Polivy · Poteligeo · Prolia · REBLOZYL · ROLVEDON · RYDAPT · Reblozyl · Revlimid · Rubraca · SANCUSO · SANDOSTATIN · SCEMBLIX · SIR-Spheres Microspheres · SOMATULINE DEPOT · SPRYCEL · SUTENT · Stivarga · Sylvant · TABRECTA · TAGRISSO · TALVEY · TALZENNA · TASIGNA · TAZVERIK · TECENTRIQ · TECVAYLI · TEFLARO · TIBSOVO · TIVDAK · TUKYSA · TUMOR LYSIS SYNDROME - DISEASE · Tavalisse · Tazverik · Trodelvy · ULTOMIRIS · Udenyca · VEGZELMA · VENCLEXTA · VERZENIO · VOTRIENT · VPRIV · VRAYLAR · VYXEOS · Vectibix · Venclexta · Vitrakvi · Vonjo · Vyloy · WELIREG · XALKORI · XARELTO · XGEVA · XOSPATA · XPOVIO · XTANDI · Xermelo · Xofigo · Xospata · ZEJULA · Zevalin · clonoSEQ · myRisk
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Hematology & oncology specialists in nearby ZIP areas
170
County median income
$134,929
Nearest hospital to ZIP centroid (approximate)
SAINT CLARE'S HOSPITAL/ DENVILLE CAMPUS
2.4 mi
2.4 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Abbasi is a mixed practice specialist, with above-average Medicare volume (top 20% in NJ), with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Abbasi experienced with pembrolizumab injection (keytruda)?
Based on Medicare claims data, Dr. Abbasi performed 17,000 pembrolizumab injection (keytruda) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Abbasi receive payments from pharmaceutical companies?
Yes. Dr. Abbasi received a total of $28,640 from 86 companies across 1,216 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Abbasi's costs compare to other hematology & oncology specialists in Mountain Lakes?
Dr. Abbasi's average Medicare payment per service is $28. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Abbasi) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Mountain Lakes
Browse hematology & oncology specialists in Mountain Lakes ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in NJ
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in NJ
Which NJ hematology & oncology specialists receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Bayer HealthCare Pharmaceuticals Inc. Payments to Doctors
See all physicians who received payments from Bayer HealthCare Pharmaceuticals Inc.
By company
Puma Biotechnology, Inc. Payments to Doctors
See all physicians who received payments from Puma Biotechnology, Inc.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology